110,000 Patient Study in North America
100,000+ Tests Performed in the U.S.
Finds Right & Left Sided Colorectal Cancers
Detects Breast Cancer in women with dense breasts
Help differentiate Prostate Cancer from benign conditions

BreastSentry & ColonSentry® are proprietary liquid biopsy tests that uses advanced gene expression (mRNA) technology for the early identification of Breast & Colorectal Cancer. They both use the patented Sentinel Principle Technology Platform.

Following our test result, if the score is elevated in a patient at average risk, there is an increased probability the patient may have a pre-cancerous lesion or cancer. Studies have shown 80-95% of patients who refuse invasive investigational test will comply with a simple blood test. BreastSentry, ColonSentry® and phi can reduce healthcare costs by more than 20% through early interventions.